Loading clinical trials...

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDPhase 1/2NCT04278144

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Lead sponsor: Bolt Biotherapeutics, Inc.•11 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 1

HER2 Vaccine for Locally Advanced Breast Cancer

NCT06949410 · Breast Cancer, HER2-positive Breast Cancer

RECRUITINGPhase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more

RECRUITINGPhase 2

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

NCT04886531 · Breast Cancer, HER2-positive Breast Cancer, and more

RECRUITINGPhase 2

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673 · Breast Cancer, HER2-positive Breast Cancer, and more

RECRUITINGPhase 1/2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

NCT04585750 · Advanced Solid Tumor, Advanced Malignant Neoplasm, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 15, 2025Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1/PHASE2

Enrollment175

Start dateFeb 2020

Last updatedSep 15, 2025

Condition

HER2-positive Solid Tumors HER2-positive Breast Cancer HER2-positive Colorectal Cancer HER2-positive Gastroesophageal Cancer HER2-positive Endometrial Cancer

Locations shown

Stanford University

Palo Alto, California

Georgetown University Medical Center

Washington D.C., District of Columbia

The University of Chicago Medical Center

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 15, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions